Help

Search Results

212 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 03

    The effect of socio-economic inequalities: modelling of population health impact of introducing reduced-risk tobacco products into Germany

    RYTSAR R.(1); DJURDJEVIC S.(1); NUSSBAUM A.(2); KAUL A.(3,4); BENNEWITZ E.(3,4)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Philip Morris GmbH, Gräfelfing, Germany; (3) Saarland University, Department of Economics, Saarbrücken, Germany; (4) IPE Institute for Policy Evaluation, Frankfurt, Germany
    Education, income and occupation are the most commonly used descriptors of social inequalities in health. The socio-economic status (SES) of individuals (or groups of individuals) has proven to be important when describing and understanding smoking...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy,...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 10

    Development of the ABOUT™–Health & Functioning: results from the preparatory phase

    SPIES E.(1); BACSO A.(1); CHREA C.(1); ABETZ-WEBB L.(2); AFOLALU E.(1); CLERC E.(1); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.
    Switching cigarette smokers to significantly less harmful tobacco or nicotine products, or reduced-risk products (RRPs), has been recognized as a valuable and promising approach to reduce smoking-related population harm. Measuring self-reported...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 11

    Development and validation of the ABOUT™–Dependence measurement instrument to assess perceived dependence on tobacco and nicotine products

    AFOLALU E.(1); CHREA C.(1); SALZBERGER T.(2); ABETZ-WEBB L.(3); CANO S.(4); WEITKUNAT R.(1); ROSE J.(5)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (4) Modus Outcomes, Letchworth Garden City, U.K.; (5) Rose Research Center, Raleigh, U.S.A.
    The development of the ABOUT™–Dependence measurement instrument was initiated to enable assessment of perceived dependence associated with the use of different tobacco and nicotine products (TNPs) and in users of multiple TNPs. We initially developed...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 16

    Selected harmful or potentially harmful constituent yields in the aerosol of commercial closed systems electronic cigarettes

    KORNELIOU A.; JACCARD G.; BELUSHKIN M.; TAFIN DJOKO D.; ESPOSITO M.; JEANNET C.; LAZZERINI M.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Over the past few years, electronic cigarettes have rapidly evolved and have been introduced in multiple markets across the world. They are thought to be a potentially less harmful alternative to cigarettes, as they heat a liquid to generate the...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 41

    Human chemical signature – investigation on the influence of human presence and selected activities on concentrations of airborne constituents

    MITOVA M.I.; GOUJON-GINGLINGER C.; ROTACH M.; MAEDER S.
    PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Available indoor air quality (IAQ) studies on tobacco- and nicotine-containing potentially reduced-risk products (PRRPs), such as electrically heated tobacco products and e-cigarettes, demonstrate substantial reduction of environmental emissions...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs)....
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 47

    A high-throughput and sensitive bioanalytical method for quantification of nicotine and cotinine in rat/mouse plasma using reversed-phase liquid chromatography–tandem mass spectrometry and its application in inhalation study sample analysis

    SAXENA A.(1); ZHANG Chunyan(1); CIPUTRA T.(1); CHNG Yun Xuan(1); PHILLIPS B.(1); VANSCHEEUWIJCK P.(2)
    (1) PMI R&D, Philip Morris International Research Laboratories Pte. Ltd., Singapore; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Nicotine and cotinine are used as primary biomarkers to estimate the exposure of reduced-risk products, such as e-liquids/heated tobacco products, in comparison with cigarettes. The objective of this study was to develop and validate a method per...